The evaluation of bone age in patients with Duchenne muscular dystrophy on long-term glucocorticoid treatment | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
Abstracts & Posters

The evaluation of bone age in patients with Duchenne muscular dystrophy on long-term glucocorticoid treatment

key information

source: Neuromuscular Disorders

year: 2015

authors: E. Annexstad, J.Westvik, A. Myhre, J. Bollerslev, I. Holm, M.Rasmussen

summary/abstract:

Long-term treatment with glucocorticoids (GCs) has a well-established effect on ambulation, prevention of scoliosis and preserved respiratory function in patients with Duchenne muscular dystrophy (DMD). However, as a new generation of GC treated DMD boys grow up to become young adults, long-term side effects of this treatment need to be addressed. A nationwide longitudinal study of paediatric DMD patients in Norway was set up to assess genotype/phenotype correlations; growth; puberty; bone health and quality of life.

organization: Centre for Congenital Neuromuscular Disorders, Norway; Oslo University Hospital, Norway

DOI: 10.1016/j.nmd.2015.06.050

read more

rareRelated